| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-12-12 | UCART19 | relapsed or refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) | 1 | Cellectis (France) Servier (France) Pfizer (USA - NY) | Cancer - Oncology |
| 2017-12-12 | TPIV200 | prevention of cancer recurrence in women with triple-negative breast cancer (TNBC) who have completed first-line surgery and radiotherapy/chemotherapy | 2 | Tapimmune (USA - FL) | Cancer - Oncology |
| 2017-12-12 | Tesomet® (tesofensine and metoprolol) | type 2 diabetes | 2a | Saniona (Denmark) | Metabolic diseases |
| 2017-12-12 | JCAR017 (lisocabtagene maraleucel) | relapsed/refractory B cell non-Hodgkin lymphoma (NHL) | 1 | Juno Therapeutics (USA - WA) | Cancer - Oncology |
| 2017-12-12 | IFN alpha Kinoid | type 1 diabetes | preclinical | Neovacs (France) | Autoimmune diseases - Metabolic diseases |
| 2017-12-12 | caplacizumab | thrombotic thrombocytopenic purpura (TTP) | 3 | Ablynx (Belgium) | Autoimmune diseases - Rare diseases |
| 2017-12-12 | UCART19 | relapsed/refractory B acute lymphoblastic leukaemia (ALL) | 1 | Cellectis (France) Servier (France) Pfizer (USA - NY) | Cancer - Oncology |
| 2017-12-11 | axicabtagene ciloleucel (KTE-C19) (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) | acute lymphoblastic leukemia (ALL) | 1-2 | Kite Pharma (USA - CA) | Cancer - Oncology |
| 2017-12-11 | crizanlizumab (SEG101) | sickle cell disease | 2 | Novartis (Switzerland) | Cancer - Oncology |
| 2017-12-11 | SPK-9001 | hemophilia B | 1-2 | Pfizer (USA - NY) Spark Therapeutics (USA - PA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-11 | BCT-197 (acumapimod) | acute exacerbations of chronic obstructive pulmonary disease | 2b | Mereo Biopharma (UK) | Infectious diseases - Respiratory diseases |
| 2017-12-11 | LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) | beta-thalassemia, sickle cell disease | 1-2 | bluebird bio (USA - MA) | Hematologic diseases - Genetic diseases - Rare diseases |
| 2017-12-11 | Adcetris® (brentuximab vedotin) and Opdivo® (nivolumab) | relapsed or refractory classical Hodgkin lymphoma | 1-2 | BMS (USA - NY) Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2017-12-11 | FP-1201-lyo (the lyophilised form of Traumakine® (human recombinant interferon-beta 1a) | acute respiratory distress syndrome (ARDS) | 3 | Faron Pharmaceuticals (Finland) | Lung diseases - Respiratory diseases - Rare diseases |
| 2017-12-11 | WVE-3972-01 | amyotrophic lateral sclerosis (ALS) frontotemporal dementia (FTD) | preclinical | Wave LIfe Sciences (USA - MA) | Rare diseases - Genetic diseases - Neurological diseases - Neurodegenerative diseases |
| 2017-12-11 | CAEL-101 (mAb 11-1F4) | amyloid light chain amyloidosis | 1b | Caelum Biosciences (USA - NY) | Rare diseases - Genetic diseases |
| 2017-12-11 | FT500 | preclinical | Fate Therapeutics (USA - CA) | Cancer - Oncology | |
| 2017-12-11 | EZM8266 | sickle cell disease (SCD) | preclinical | Epizyme (USA - MA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-12-10 | polatuzumab vedotin | people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for hematopoietic stem cell transplant. | 1b-2 | Roche (Switzerland) | Cancer - Oncology |
| 2017-12-10 | CTX001 | Beta-thalassemia, sickle cell disease | preclinical | Crispr Therapeutics (Switzerland - UK) | Rare diseases - Genetic diseases - Hematological diseases |
